Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma
Figure 6
The use of sunitinib and/or telmisartan does not change tumor proliferation or phosphorylation of ERK and AKT. (a) Tumor analysis by Ki67 staining (×200) in control tumor and after treatment with sunitinib alone, telmisartan alone, and in combination. No difference between groups is observed. (b) Analysis of proteins ERK1/2, AkT, p-ERK1/2, and p-AKT from tumor control and treated group.